

FOR IMMEDIATE RELEASE

Contact: Vartan Ghazarossian, Ph.D.
President and CEO
FlowMedica, Inc.
(510) 252-9500
info@FlowMedica.com

FLOWMEDICA ANNOUNCES POST-MARKET STUDY OF ITS *BENEPHIT*[™] INFUSION SYSTEM Aim is to Preserve Kidney Function During Medical Procedures

FREMONT, CA – March 30, 2004 – FlowMedica, Inc., a medical device company developing intravascular systems for facilitating the management of life-threatening renal conditions, today announced the initiation of a post-market clinical study of its FlowMedica *Benephit*[™] Infusion System, a proprietary infusion catheter system for delivering therapeutic agents directly to the kidneys via the renal arteries.

Numerous institutions are participating in this physician-sponsored, randomized study. Hooman Madyoon, M.D., an interventional cardiologist affiliated with Cedars-Sinai and Brotman Medical Centers in Los Angeles, CA and St. Joseph's Medical Center in Stockton, CA, enrolled the first patient earlier this month. Participating physicians are evaluating the system's ability to deliver a vasodilator drug selectively to the kidneys to prevent certain changes in kidney physiology associated with radiocontrast nephropathy (RCN) – a common cause of acute kidney failure among patients undergoing coronary interventional and diagnostic procedures. RCN occurs when the kidneys of patients with renal insufficiency or diabetes are unable to process the radiocontrast agents used during these procedures, resulting in impaired kidney function and increased morbidity and mortality.

“The FlowMedica *Benephit* Infusion System could be valuable in treating patients with renal insufficiency who are in need of cardiovascular care,” said Dr. Madyoon. “The use of this system to deliver protective agents to the kidneys may allow interventionalists to administer higher, more effective doses of these drugs than we can safely provide systemically.”

“RCN is a growing problem among hospitalized patients, as the number of interventional procedures performed annually in the U.S. is increasing rapidly,” stated Martin B. Leon, M.D., FACC, Director and Chief Executive Officer of the Cardiovascular Research Foundation at the Lenox Hill Heart and Vascular Institute in New York. Dr. Leon is also a member of the Physician Founder Board of Accelerated Technologies, Inc., which founded FlowMedica. “It is estimated that one-third of all patients undergoing coronary interventions and one-fifth of those receiving coronary angiograms are at higher risk of developing RCN.”

The FlowMedica *Benephit* Infusion System recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the infusion of physician-specified agents

in the peripheral vasculature and is initially being evaluated for its ability to prevent RCN. The system delivers therapeutic agents directly to the renal arteries through a dedicated Bifurcated Infusion Catheter, allowing simultaneous coronary procedures and therapeutic agent infusion through a single access site in the femoral artery via a unique Introducer Sheath.

About Radiocontrast Nephropathy

One of the most common causes of acute renal failure among hospitalized patients, RCN occurs when patients' kidneys are unable to process the iodinated radiocontrast media administered during coronary interventional and diagnostic procedures. Consequently, kidney function is compromised and waste products build up in the bloodstream. RCN is associated with prolonged hospital stays, increased morbidity and mortality, and higher medical costs.

Worldwide, the number of contrast media-enhanced coronary examinations and interventions executed annually is large and rising; more than seven million procedures using iodinated radiocontrast media are performed each year. It is estimated that approximately one million patients worldwide undergoing these procedures are at risk of developing RCN each year.

About FlowMedica

FlowMedica is a venture-backed, privately held medical device company developing intravascular systems for facilitating the management of life-threatening renal conditions associated with cardiovascular disease, cancer, and surgery. The company's initial product is the FlowMedica *Benephit* Infusion System, a proprietary site-specific therapeutic agent infusion catheter system. Physicians are evaluating the system's ability to treat and prevent acute renal failure related to cardiovascular procedures, congestive heart failure, transplantation, and surgery, as well as to facilitate cancer treatment. Founded in 2002 by Accelerated Technologies, Inc., FlowMedica has raised a total of \$8.5 million to date in venture capital funding from Medica Venture Partners, Medical Imaging Innovation & Investments, L.P., and Oxford Bioscience Partners.

###